Latest news with #SamsungBiologics
UPI
7 days ago
- Business
- UPI
South Korea's Samsung Biologics, Celltrion log stellar performances
1 of 2 | South Korean biopharmaceutical contract manufacturer Samsung Biologics posted a stellar performance in the first half of this year. Photo courtesy of Samsung Biologics SEOUL, July 24 (UPI) -- The South Korean economy struggles as the country's gross domestic product growth rate is feared to more than halve to less than 1% this year, compared to 2% for 2024. However, its defense and shipbuilding industries are faring well. Also among the high achievers are biopharmaceutical contract manufacturers, including Samsung Biologics and Celltrion. Samsung Biologics, one of the world's largest contract development and manufacturing organizations, or CDMOs, announced Wednesday that it posted record-high $1.88 billion in sales during the first six months of 2025, up 21.3% from a year earlier. Its operating profit amounted to $700 million, up 46.75%. The company also said that it has signed contracts worth $2.4 billion in the first half of the year, which is more than 60% of its total annual order volume for 2024. "As global demand for CDMO services continues to rise, we are rapidly expanding our production capacity," Samsung Biologics said in a statement. "Backed by our world-class CDMO capabilities, we plan to intensify our efforts to win more orders, particularly targeting the world's top 40 pharmaceutical companies." Samsung's local rival, Celltrion, is likewise seeing impressive results. The outfit announced Tuesday that its first-half turnover stood at $1.31 billion, up 11.9% year-on-year. Its operating income more than tripled to $285 million. The company's sales for this year are expected to top $3 billion for the first time, and its bottom line is projected to near the $1 billion mark. Observers have positive outlooks for the two powerhouses. "Samsung Biologics is beefing up its global competitiveness through the second campus, which includes plants five to eight," KB Securities researcher Kim Hye-min said in a market report. "The company is also expanding its capabilities beyond traditional monoclonal antibody-focused CDMO services to next-generation modalities and pre-filled syringes," she noted. Prefilled syringe manufacturing means that Samsung Biologics rolls out drugs in ready-to-inject formats. Global pharmaceutical clients tend to request this for chronic diseases or biologic treatments. Regarding Celltrion, Heungkuk Securities analyst Lee Ji-won said in a recent report that this year would be a pivotal point for the company's profit growth momentum. "Celltrion is predicted to demonstrate a significant year-on-year increase in profits, driven by the solid performance of newly launched high-margin biosimilars," Lee said. Experts said the CDMO businessm which is based on outsourced manufacturing, is an area in which Korean companies have advantages. "Although the Korean economy languishes due to various reasons this year, the biopharmaceutical outsourcing business is likely to rack up stellar performances for the time being. Samsung Biologics and Celltrion will spearhead the trend," Seoul-based business tracker Leaders Index CEO Park Ju-gun told UPI. "Samsung Biologics has already become an established player in the market, favored by global biopharmaceutical giants thanks to its cost competitiveness and quick delivery. Celltrion is also trying hard to become a big name in the market," he said. Economic analyst Kim Joon-Kyung, formerly vice chairman at Deloitte Consulting Korea, agreed. "First of all, the CDMO industry is promising. And from the perspective of Samsung, the business shares many characteristics with semiconductor production. Hence, the group had a good reason to tap into the CDMO sector," Kim said in a phone interview. "Celltrion did not have such advantages. But the company secured technological edges early on, which is quite an achievement. That's why Celltrion is showing solid performances now," he said. Samsung Electronics, the mother company of Samsung Biologics, is the world's largest maker of memory chips. According to U.S. market intelligence firm BCC Research, the global CDMO market is expected to expand to $191.6 billion by 2029 from $136.6 billion last year based on mounting demand for outsourced drug development and manufacturing. Other biopharmaceutical companies in Korea also are striving to tap into the lucrative CDMO business, including SK Bioscience and Lotte Biologics. Toward that end, SK Bioscience acquired a controlling stake in IDT Biologika of Germany, which is one of the top 10 global vaccine CDMOs, late last year. Lotte Biologics has launched operations of its antibody-drug conjugate facility at its Syracuse Bio Campus in the United States. The company also is preparing its first plant located just west of Seoul, aiming to begin commercial production in 2027.
Korea Herald
23-07-2025
- Business
- Korea Herald
Samsung Biologics reports second quarter 2025 financial results
INCHEON, South Korea, July 23, 2025 /PRNewswire/ -- Samsung Biologics (KRX: a leading contract development and manufacturing organization (CDMO), today announced its financial results for the second quarter of fiscal year 2025. "Our second quarter results demonstrate continued strong momentum across our business," said John Rim, CEO and President of Samsung Biologics. "With Plant 5 now fully operational, we are leveraging our manufacturing expertise and expanded capacity to deliver seamless, end-to-end CDMO services at scale. We have broadened our portfolio with advancements in antibody-drug conjugates (ADCs) and the launch of research services, Samsung Organoids, further reinforcing our ability to offer a wider range of innovative solutions to clients. Additionally, we are redefining digitalization in biomanufacturing, harnessing advanced digital tools to deliver greater transparency, speed, and value—setting new standards in the industry. These strategic initiatives will continue to strengthen our ability to accelerate client pipelines, while fostering enduring partnerships grounded in quality and operational excellence." SECOND QUARTER 2025 RESULTS Samsung Biologics posted consolidated revenue of KRW 1,289.9 billion and operating profit of KRW 475.6 billion in the second quarter of 2025. On a standalone basis, the company reported revenue of KRW 1,014.2 billion and operating profit of KRW 477.0 billion. The growth was buoyed by the full utilization of Plants 1 through 3 and the continued ramp-up of Plant 4. In the first half of 2025, standalone revenue surpassed KRW 2 trillion, reflecting consistent momentum across all manufacturing plants. Sales contract volume in the first half reached USD 2.4 billion, bringing up the cumulative value to USD 18.7 billion. BUSINESS UPDATES In April, Samsung Biologics added 180 kL of capacity with Plant 5 to better meet clients' manufacturing needs. The facility, equipped with advanced automation and digital systems, integrates best practices and features from existing plants to ensure consistent operations and the highest quality standards. The company also broadened its service offering with the launch of research services, Samsung Organoids, which utilizes patient-derived organoids to support drug discovery and development. Samsung Organoids enables precision screening to predict patient-specific drug responses and provides clients with multi-modal insights to effectively support early-stage decision making. In May, Samsung Biologics announced plans to spin off its wholly-owned subsidiary, Samsung Bioepis. Through the financial and legal separation, the company will focus on strengthening its core capabilities as a pure-play CDMO, enhancing customer satisfaction and proactively responding to the industry's greater demands to ultimately maximize corporate value and sustainable growth potential. On the sustainability front, the company released its 2025 ESG report in June, outlining progress in areas including enhanced disclosure standards, an accelerated path to net-zero, and TNFD-aligned risk management. As part of its decarbonization efforts, Samsung Biologics achieved a 24% reduction in greenhouse gas emissions in 2024 compared to the previous year and increased its renewable energy use to 29% of total electricity consumption. The company also signed an additional solar Power Purchase Agreement to further support its energy transition. Beyond operations, Samsung Biologics is actively engaged in collaborative efforts through the Sustainable Market Initiative to decarbonize healthcare supply chains and promote global environmental responsibility. About Samsung Biologics Samsung Biologics (KRX: is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 784 kL across five plants, Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. Samsung Biologics operates a global network with facilities and offices in Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality products, as well as making sustainable business decisions for the betterment of society and global health.
Time Business News
23-07-2025
- Business
- Time Business News
Biologics CDMO Surges with Chronic Disease Rise and Innovation Demand
Biologics have made major impact when it comes to tackling the inflammation that causes so much damage to joints and other organs in conditions like arthritis and other inflammatory diseases. Companies specializing in Biologics CDMO, or Contract Development and Manufacturing Organizations, provide crucial services in developing and manufacturing these biological medical products for the pharmaceutical industry. Increasing cases of chronic diseases and growth in ageing population has contributed in market growth. Growing demand for novel therapies and need for huge capital investment for innovative & advanced technologies in pharmaceutical companies is further expected to provide lucrative opportunities in Biologics CDMO domain. Key Growth Drivers and Opportunities Rising Prevalence of Cancer Diseases: Growing prevalence of cancer diseases has become a major factor in Biologics CDMO market growth. Different types of cancer are on the rise due to poor and unhealthy lifestyles. Breast cancer, lung cancer, liver and kidney cancer, and pancreatic cancer are on the rise. For instance, according to Center for Disease and Control and Prevention (CDC), In the United States in 2019, 1,752,735 new cancer cases were reported and 599,589 people died of cancer. Emerging Pharmaceutical and Biotech Companies: Increasing need for CDMOs from emerging pharmaceutical and biotech companies has boosted the target market's growth. The rise in the number of clinical trials has become a major driver of target market expansion. According to Food and Drug Administration (FDA) there are around 50 ongoing clinical trials in cell and gene therapy by major and emerging biotech or pharmaceutical companies. Challenges There are several challenges faced by CDMOs, are cost pressure, fierce competition, consolidation, and constant technological innovations, which may hamper the market growth. The wrong innovative CDMO solution provider may lead to a bad customer experience and variations in the standards of customer service may lead to quality problems. Moreover, this may also lead to less control over the production process, which act as a challenges and disadvantages of CDMOs which in turn hampered the demand for Biologics CDMO Innovation and Expansion Samsung Wins USD 183 Mn Pfizer Vaccine Deal In March 2023, Samsung Biologics signed a deal Pfizer to manufacture COVID-19 vaccines for Moderna. The value of the contract is USD 183 million and will run through the year 2029. This new deal worth 15% of Samsung's USD 1.2 billion revenue from 2021 year. Given initiative shows how much Samsung Biologics is stepping up as a top player in the global CDMO scene. It also makes Pfizer's supply chain much more robust when it comes to mRNA vaccines. Plus, this long-term partnership is a clear sign that both companies are committed to being ready for future pandemics. Lonza Invests $518M in Swiss Biologics Expansion In July 2022, Lonza has planned to spend USD 518 million on a large-scale fill-finish manufacturing plant in Stein, Switzerland. This new facility is set to greatly enhance Lonza's capabilities in making sterile drug products. It's specifically built to meet the growing demand for complex biologics and advanced therapies. This investment further strengthens Switzerland's reputation as a global leader in the biopharmaceutical sector. Inventive Sparks, Expanding Markets The key players operating the biologics CDMO market includes, Lonza Group, Catalent Inc., Samsung Biologics, Eurofins Scientific, Boehringer Ingelheim Group, FUJIFILM Diosynth Biotechnologies Inc., among others. Biologics CDMO companies are all about speeding up the process of creating new drugs, making sure that high-quality manufacturing can easily expand to meet demand for complex treatments. Their main goals are to foster innovation, improve efficiency, and help make healthcare accessible worldwide. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Korea Herald
11-07-2025
- Business
- Korea Herald
Samyang's hot streak: Global Buldak craze sends stock to record high
Shares of Samyang Foods topped the 1.5 million won ($1,090) mark, rising nearly 50 percent in just two months, as investors bet on the enduring global popularity of its hot chicken noodles, Buldak. On Thursday, the stock hit an intraday high of 1,502,000 won before closing at 1,494,000 won on the benchmark Kospi. It opened at 1,503,000 won on Friday and briefly notched a new all-time high of 1,535,000 won. As of 11 a.m. Friday, shares had eased to 1,470,000 won. The rally extends a blistering run for Samyang, which passed the 1 million won mark on May 12, a milestone that places the food maker alongside Samsung Biologics as a company with seven-figure share prices. Analysts credit the surge to expectations of strong quarterly earnings and increased production capacity. "The company's new facility will drive earnings growth as Buldak production scales up exports to the US and Europe from the third quarter," an analyst from Korea Investment & Securities noted. Sales growth was limited in the first quarter due to supply constraints in the US and Europe, the analyst added, suggesting a sharp pickup ahead. In June, Samyang's new plant in Miryang, South Gyeongsang Province, came online to supply the US and European markets. The noodle maker currently produces all of its products in Korea but is building its first overseas plant in China, slated for completion in 2027. A Kyobo Securities analyst also offered an upbeat outlook: 'Given Samyang's strong global recognition, there appears to be ample room for further upward revisions in its valuation.' Last year, Samyang's annual sales rose 45 percent to 1.73 trillion won, with operating profit soaring 133 percent to 344.2 billion won. Overseas sales reached a record 1.33 trillion won, making up nearly 80 percent of total revenue. In the US, sales doubled to $280 million; sales in China surged 75 percent to $290 million. According to financial information provider FN Guide, Samyang Foods' operating profit for the first half of this year is projected to jump 55.4 percent on-year to 263.5 billion won, with revenue projected to rise 32.2 percent to 1.07 trillion won.
Korea Herald
25-06-2025
- Business
- Korea Herald
Seoul shares open lower despite overnight Wall Street gains
South Korean stocks opened slightly lower Wednesday despite overnight US stocks gains boosted by eased Middle Eastern tensions and hopes of an early interest rate cut. The benchmark Korea Composite Stock Price Index shed 1.31 points, or 0.04 percent, to 3,102.33 in the first 15 minutes of trading. Overnight, Wall Street gained ground as investors focused on easing tensions in the Middle East following the ceasefire between Israel and Iran, and the possibility of an early interest rate cut raised by US Federal Reserve Chair Jerome Powell during a testimony at the U.S Congress. In Seoul, overall losses were led by bio and battery shares. Top bio company Samsung Biologics fell 1 percent, and leading battery manufacturer LG Energy Solution lost 1.5 percent. Financial and internet portal shares also retreated. Kookmin Financial dropped 2.14 percent, and top portal operator Naver slumped 3.1 percent. In contrast, semiconductor shares continued their upward momentum from the previous session. Market heavyweight Samsung Electronics and chip rival SK hynix rose 0.5 percent and 2.69 percent, respectively. Kakao Pay also surged 14.18 percent on hopes that the online lender could benefit from the government's push to adopt won-pegged stablecoins. The local currency was trading at 1,357.25 won against the greenback at 9:15 a.m., up 2.95 won from the previous session. (Yonhap)
